"Hydralazine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A direct-acting vasodilator that is used as an antihypertensive agent.
| Descriptor ID |
D006830
|
| MeSH Number(s) |
D03.383.710.605.500
|
| Concept/Terms |
Hydralazine- Hydralazine
- Hydrallazin
- Hydrazinophthalazine
- Apressin
|
Below are MeSH descriptors whose meaning is more general than "Hydralazine".
Below are MeSH descriptors whose meaning is more specific than "Hydralazine".
This graph shows the total number of publications written about "Hydralazine" by people in this website by year, and whether "Hydralazine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydralazine" by people in Profiles.
-
Ofili E, Anand I, Williams RA, Akinboboye O, Xu L, Puckrein G. Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure. Adv Ther. 2017 08; 34(8):1976-1988.
-
Ferdinand KC, Elkayam U, Mancini D, Ofili E, Pi?a I, Anand I, Feldman AM, McNamara D, Leggett C. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African-American Heart Failure Trial. Am J Cardiol. 2014 Jul 01; 114(1):151-9.
-
McNamara DM, Tam SW, Sabolinski ML, Tobelmann P, Janosko K, Venkitachalam L, Ofili E, Yancy C, Feldman AM, Ghali JK, Taylor AL, Cohn JN, Worcel M. Endothelial nitric oxide synthase (NOS3) polymorphisms in African Americans with heart failure: results from the A-HeFT trial. J Card Fail. 2009 Apr; 15(3):191-8.
-
Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, Adams K, Olukotun AY, Ofili E, Tam SW, Sabolinski ML, Worcel M, Cohn JN. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007 Apr 03; 115(13):1747-53.
-
Taylor AL, Lindenfeld J, Ziesche S, Walsh MN, Mitchell JE, Adams K, Tam SW, Ofili E, Sabolinski ML, Worcel M, Cohn JN. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol. 2006 Dec 05; 48(11):2263-7.
-
Franciosa JA, Taylor AL, Cohn JN, Yancy CW, Ziesche S, Olukotun A, Ofili E, Ferdinand K, Loscalzo J, Worcel M. African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail. 2002 Jun; 8(3):128-35.
-
Chen J, Kuhlencordt PJ, Astern J, Gyurko R, Huang PL. Hypertension does not account for the accelerated atherosclerosis and development of aneurysms in male apolipoprotein e/endothelial nitric oxide synthase double knockout mice. Circulation. 2001 Nov 13; 104(20):2391-4.
-
Vargas HM, Cuevas JM, Ignarro LJ, Chaudhuri G. Comparison of the inhibitory potencies of N(G)-methyl-, N(G)-nitro- and N(G)-amino-L-arginine on EDRF function in the rat: evidence for continuous basal EDRF release. J Pharmacol Exp Ther. 1991 Jun; 257(3):1208-15.